Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10010

Result Summary for APV10010

Result Summary

Protocol ID:	APV10010
Clinical Study ID:	APV10010
Official Title:	A Phase I, Randomized Study to Assess the Effect of Efavirenz 600mg QD on Steady-State Plasma Total Amprenavir Pharmacokinetics Following Co-administration with GW433908 700mg BID + Ritonavir 100mg BID or GW433908 700mg BID + Ritonavir 200mg BID for 14 Days as Compared to GW433908 700mg BID + RT ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Wire MB. Ballow C. Preston SL. Hendrix CW. Piliero PJ. Lou Y. Stein DS. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS. 18(6):897-907, 2004. Abstract: An assessment of plasma amprenavir (apv) pharmacokinetics (pk) following administration of two gw433908 (908) and ritonavir (rtv) regimens in combination with efavirenz (efv) in healthy adult subjects apv10010). Wire, M B, Ballow, C, Preston, S, Hendrix, C, Lou, Y, Piliero, P, and Stein, DS 9th Annual Conference on Retroviruses and Opportunistic Infections 2/24/2002 Seattle, WA; USA